All News

According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

Treatment with sunvozertinib showed improvement across all secondary end points among those with EGFR exon 20 insertion mutation–positive NSCLC.

COVID-19 and HIV reshaped cancer care, leading to delayed screenings, a surge in telehealth, mental health strain, and equity lessons, many of which clinicians still confront.

Experts explore the complexities of cannabis use, the financial impact, and best practices for administration in patients with cancer.

In the first-cycle of chemotherapy, patients under 40 were more likely to have higher rates of nausea/vomiting.

Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

Learn SCAC risk factors, rising trends, and new frontline retifanlimab chemoimmunotherapy, plus PD‑1 options and emerging checkpoint strategies.

Historically, 30% to 60% of AYA patients with cancer experience sexual dysfunction.

A panel of experts convened to explore the practical integration of BCMA-directed bispecific antibodies into clinical care for patients with multiple myeloma.

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

Three Neuroendocrine Tumor Research Foundation grant winners outlined research that aimed to deliver biology-driven strategies to patients.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

It’s unlikely guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

The resubmission occurred after discussions with the FDA in January 2026, where the agency requested additional data to support its review.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

The NHS-Galleri study showed that multi-cancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

Rusfertide could become a part of every patient’s treatment history for polycythemia vera, according to Andrew Kuykendall, MD.

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.

Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.

Donor availability may influence the treatment decision-making process regarding the use of transplantation for those with myelofibrosis.

This study aims to understand the degree of influence of the severity of lymphedema on quality of life in patients with breast cancer–related lymphedema during the maintenance phase.

Sacituzumab govitecan and pembrolizumab were recommended as category 1 regimens for metastatic triple-negative breast cancers based on 2 phase 3 trials.

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.